Skip to main content
Top
Published in: Digestive Diseases and Sciences 12/2015

01-12-2015 | Original Article

Protease-Activated Receptor-2 Up-Regulates Transient Receptor Potential Vanilloid 4 Function in Mouse Esophageal Keratinocyte

Authors: Nobuhiro Suzuki, Hiroshi Mihara, Hirofumi Nishizono, Makoto Tominaga, Toshiro Sugiyama

Published in: Digestive Diseases and Sciences | Issue 12/2015

Login to get access

Abstract

Background

The reflux of pancreatic–duodenal fluids is implicated in the pathophysiology of proton-pump inhibitor-resistant gastroesophageal reflux disease (GERD). Protease-activated receptor-2 (PAR-2) is activated by proteases, the pancreatic enzyme, trypsin, and the activated PAR-2 enhances transient receptor potential vanilloid 4 (TRPV4) function in neurons. TRPV4 stimulates ATP exocytosis in conjunction with the vesicular nucleotide transporter, which mediates mechano-transduction and vagal stimulation. The aim of the present study was to verify whether the activated PAR-2 up-regulates TRPV4 function in mouse esophageal keratinocytes, which may link to the pathophysiology in PPI-resistant GERD.

Methods

TRPV4 and PAR-2 expressions were detected by RT-PCR, immunostaining, and western blotting in mouse esophageal keratinocytes. The functional response of TRPV4 to esophageal keratinocytes was analyzed using a Ca2+ imaging system. Cellular ATP release was examined by luciferase–luciferin reaction. TRPV4 phosphorylation was studied by immunoprecipitation and western blotting.

Results

PAR-2 and TRPV4 mRNAs and proteins were expressed in esophageal keratinocytes. Pre-treatment with trypsin significantly increased the responses to TRPV4 activator in esophageal keratinocytes, probably via the phosphorylation of serine residue of TRPV4 by protein kinase C and resulted in cellular ATP release from the cells.

Conclusions

Activated PAR-2 with trypsin exposure up-regulated TRPV4 function and increased ATP release in mouse esophageal keratinocytes. This mechanism might be related to the pathophysiology of GERD, especially non-erosive GERD.
Appendix
Available only for authorised users
Literature
1.
go back to reference Kinoshita Y, Adachi K, Hongo M, et al. Systematic review of the epidemiology of gastroesophageal reflux disease in Japan. J Gastroenterol. 2011;46:1092–1103.CrossRefPubMed Kinoshita Y, Adachi K, Hongo M, et al. Systematic review of the epidemiology of gastroesophageal reflux disease in Japan. J Gastroenterol. 2011;46:1092–1103.CrossRefPubMed
3.
go back to reference Martinez SD, Malagon IB, Garewal HS, et al. Non-erosive reflux disease (NERD)–acid reflux and symptom patterns. Aliment Pharmacol Ther. 2003;17:537–545.CrossRefPubMed Martinez SD, Malagon IB, Garewal HS, et al. Non-erosive reflux disease (NERD)–acid reflux and symptom patterns. Aliment Pharmacol Ther. 2003;17:537–545.CrossRefPubMed
4.
go back to reference Dean BB, Gano AD Jr, Knight K, et al. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol. 2004;2:656–664.CrossRefPubMed Dean BB, Gano AD Jr, Knight K, et al. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol. 2004;2:656–664.CrossRefPubMed
5.
go back to reference Furuta T, Shimatani T, Sugimoto M, et al. Investigation of pretreatment prediction of proton pump inhibitor (PPI)-resistant patients with gastroesophageal reflux disease and the dose escalation challenge of PPIs-TORNADO study: a multicenter prospective study by the Acid-Related Symptom Research Group in Japan. J Gastroenterol. 2011;46:1273–1283.CrossRefPubMed Furuta T, Shimatani T, Sugimoto M, et al. Investigation of pretreatment prediction of proton pump inhibitor (PPI)-resistant patients with gastroesophageal reflux disease and the dose escalation challenge of PPIs-TORNADO study: a multicenter prospective study by the Acid-Related Symptom Research Group in Japan. J Gastroenterol. 2011;46:1273–1283.CrossRefPubMed
7.
go back to reference Koek GH, Tack J, Sifrim D, et al. The role of acid and duodenal gastroesophageal reflux in symptomatic GERD. Am J Gastroenterol. 2001;96:2033–2040.CrossRefPubMed Koek GH, Tack J, Sifrim D, et al. The role of acid and duodenal gastroesophageal reflux in symptomatic GERD. Am J Gastroenterol. 2001;96:2033–2040.CrossRefPubMed
8.
go back to reference Tack J, Koek G, Demedts I, et al. Gastroesophageal reflux disease poorly responsive to single-dose proton pump inhibitors in patients without Barrett’s esophagus: acid reflux, bile reflux, or both? Am J Gastroenterol. 2004;99:981–988.CrossRefPubMed Tack J, Koek G, Demedts I, et al. Gastroesophageal reflux disease poorly responsive to single-dose proton pump inhibitors in patients without Barrett’s esophagus: acid reflux, bile reflux, or both? Am J Gastroenterol. 2004;99:981–988.CrossRefPubMed
9.
go back to reference Trimble KC, Pryde A, Heading RC. Lowered oesophageal sensory thresholds in patients with symptomatic but not excess gastro-oesophageal reflux: evidence for a spectrum of visceral sensitivity in GORD. Gut. 1995;37:7–12.PubMedCentralCrossRefPubMed Trimble KC, Pryde A, Heading RC. Lowered oesophageal sensory thresholds in patients with symptomatic but not excess gastro-oesophageal reflux: evidence for a spectrum of visceral sensitivity in GORD. Gut. 1995;37:7–12.PubMedCentralCrossRefPubMed
10.
go back to reference Everaerts W, Nilius B, Owsianik G. The vanilloid transient receptor potential channel TRPV4: From structure to disease. Prog Biophys Mol Biol. 2010;103:2–17.CrossRefPubMed Everaerts W, Nilius B, Owsianik G. The vanilloid transient receptor potential channel TRPV4: From structure to disease. Prog Biophys Mol Biol. 2010;103:2–17.CrossRefPubMed
11.
go back to reference Mihara H, Boudaka A, Sugiyama T, et al. Transient receptor potential vanilloid 4 (TRPV4)-dependent calcium influx and ATP release in mouse oesophageal keratinocytes. J Physiol. 2011;589:3471–3482.PubMedCentralCrossRefPubMed Mihara H, Boudaka A, Sugiyama T, et al. Transient receptor potential vanilloid 4 (TRPV4)-dependent calcium influx and ATP release in mouse oesophageal keratinocytes. J Physiol. 2011;589:3471–3482.PubMedCentralCrossRefPubMed
12.
go back to reference Zagorodnyuk VP, Chen BN, Costa M, et al. Mechanotransduction by intraganglionic laminar endings of vagal tension receptors in the guinea-pig oesophagus. J Physiol. 2003;553:575–587.PubMedCentralCrossRefPubMed Zagorodnyuk VP, Chen BN, Costa M, et al. Mechanotransduction by intraganglionic laminar endings of vagal tension receptors in the guinea-pig oesophagus. J Physiol. 2003;553:575–587.PubMedCentralCrossRefPubMed
13.
go back to reference Bielefeldt K, Davis BM. Differential effects of ASIC3 and TRPV1 deletion on gastroesophageal sensation in mice. Am J Physiol Gastrointest Liver Physiol. 2008;294:G130–G138.CrossRefPubMed Bielefeldt K, Davis BM. Differential effects of ASIC3 and TRPV1 deletion on gastroesophageal sensation in mice. Am J Physiol Gastrointest Liver Physiol. 2008;294:G130–G138.CrossRefPubMed
14.
go back to reference Krarup AL, Ny L, Astrand M, et al. Randomised clinical trial: the efficacy of a transient receptor potential vanilloid 1 antagonist AZD1386 in human oesophageal pain. Aliment Pharmacol Ther. 2011;33:1113–1122.CrossRefPubMed Krarup AL, Ny L, Astrand M, et al. Randomised clinical trial: the efficacy of a transient receptor potential vanilloid 1 antagonist AZD1386 in human oesophageal pain. Aliment Pharmacol Ther. 2011;33:1113–1122.CrossRefPubMed
15.
go back to reference Everaerts W, Zhen X, Ghosh D, et al. Inhibition of the cation channel TRPV4 improves bladder function in mice and rats with cyclophosphamide-induced cystitis. Proc Natl Acad Sci USA. 2010;107:19084–19089.PubMedCentralCrossRefPubMed Everaerts W, Zhen X, Ghosh D, et al. Inhibition of the cation channel TRPV4 improves bladder function in mice and rats with cyclophosphamide-induced cystitis. Proc Natl Acad Sci USA. 2010;107:19084–19089.PubMedCentralCrossRefPubMed
16.
go back to reference Fichna J, Mokrowiecka A, Cygankiewicz AI, et al. Transient receptor potential vanilloid 4 blockade protects against experimental colitis in mice: a new strategy for inflammatory bowel diseases treatment? Neurogastroenterol Motil. 2012;24:e557–e560.CrossRefPubMed Fichna J, Mokrowiecka A, Cygankiewicz AI, et al. Transient receptor potential vanilloid 4 blockade protects against experimental colitis in mice: a new strategy for inflammatory bowel diseases treatment? Neurogastroenterol Motil. 2012;24:e557–e560.CrossRefPubMed
17.
go back to reference Ramachandran R, Noorbakhsh F, Defea K, et al. Targeting proteinase-activated receptors: therapeutic potential and challenges. Nat Rev Drug Discov. 2012;11:69–86.CrossRefPubMed Ramachandran R, Noorbakhsh F, Defea K, et al. Targeting proteinase-activated receptors: therapeutic potential and challenges. Nat Rev Drug Discov. 2012;11:69–86.CrossRefPubMed
18.
go back to reference Kandulski A, Wex T, Monkemuller K, et al. Proteinase-activated receptor-2 in the pathogenesis of gastroesophageal reflux disease. Am J Gastroenterol. 2010;105:1934–1943.CrossRefPubMed Kandulski A, Wex T, Monkemuller K, et al. Proteinase-activated receptor-2 in the pathogenesis of gastroesophageal reflux disease. Am J Gastroenterol. 2010;105:1934–1943.CrossRefPubMed
20.
go back to reference Grant AD, Cottrell GS, Amadesi S, et al. Protease-activated receptor 2 sensitizes the transient receptor potential vanilloid 4 ion channel to cause mechanical hyperalgesia in mice. J Physiol. 2007;578:715–733.PubMedCentralCrossRefPubMed Grant AD, Cottrell GS, Amadesi S, et al. Protease-activated receptor 2 sensitizes the transient receptor potential vanilloid 4 ion channel to cause mechanical hyperalgesia in mice. J Physiol. 2007;578:715–733.PubMedCentralCrossRefPubMed
21.
go back to reference Kono K, Takahashi A, Sugai H, et al. Oral trypsin inhibitor can improve reflux esophagitis after distal gastrectomy concomitant with decreased trypsin activity. Am J Surg. 2005;190:412–417.CrossRefPubMed Kono K, Takahashi A, Sugai H, et al. Oral trypsin inhibitor can improve reflux esophagitis after distal gastrectomy concomitant with decreased trypsin activity. Am J Surg. 2005;190:412–417.CrossRefPubMed
22.
go back to reference Mizuno A, Matsumoto N, Imai M, et al. Impaired osmotic sensation in mice lacking TRPV4. Am J Physiol Cell Physiol. 2003;285:C96–C101.CrossRefPubMed Mizuno A, Matsumoto N, Imai M, et al. Impaired osmotic sensation in mice lacking TRPV4. Am J Physiol Cell Physiol. 2003;285:C96–C101.CrossRefPubMed
23.
go back to reference Kawao N, Nagataki M, Nagasawa K, et al. Signal transduction for proteinase-activated receptor-2-triggered prostaglandin E2 formation in human lung epithelial cells. J Pharmacol Exp Ther. 2005;315:576–589.CrossRefPubMed Kawao N, Nagataki M, Nagasawa K, et al. Signal transduction for proteinase-activated receptor-2-triggered prostaglandin E2 formation in human lung epithelial cells. J Pharmacol Exp Ther. 2005;315:576–589.CrossRefPubMed
24.
go back to reference Miwa H, Kondo T, Oshima T, et al. Esophageal sensation and esophageal hypersensitivity—overview from bench to bedside. J Neurogastroenterol Motil. 2010;16:353–362.PubMedCentralCrossRefPubMed Miwa H, Kondo T, Oshima T, et al. Esophageal sensation and esophageal hypersensitivity—overview from bench to bedside. J Neurogastroenterol Motil. 2010;16:353–362.PubMedCentralCrossRefPubMed
25.
go back to reference Farre R. Pathophysiology of gastro-esophageal reflux disease: a role for mucosa integrity? Neurogastroenterol Motil. 2013;25:783–799.PubMed Farre R. Pathophysiology of gastro-esophageal reflux disease: a role for mucosa integrity? Neurogastroenterol Motil. 2013;25:783–799.PubMed
28.
go back to reference Ueda T, Shikano M, Kamiya T, et al. The TRPV4 channel is a novel regulator of intracellular Ca2+ in human esophageal epithelial cells. Am J Physiol Gastrointest Liver Physiol. 2011;301:G138–G147.CrossRefPubMed Ueda T, Shikano M, Kamiya T, et al. The TRPV4 channel is a novel regulator of intracellular Ca2+ in human esophageal epithelial cells. Am J Physiol Gastrointest Liver Physiol. 2011;301:G138–G147.CrossRefPubMed
29.
go back to reference Weijenborg PW, Bredenoord AJ. How reflux causes symptoms: reflux perception in gastroesophageal reflux disease. Best Pract Res Clin Gastroenterol. 2013;27:353–364.CrossRefPubMed Weijenborg PW, Bredenoord AJ. How reflux causes symptoms: reflux perception in gastroesophageal reflux disease. Best Pract Res Clin Gastroenterol. 2013;27:353–364.CrossRefPubMed
30.
go back to reference Page AJ, O’Donnell TA, Blackshaw LA. P2X purinoceptor-induced sensitization of ferret vagal mechanoreceptors in oesophageal inflammation. J Physiol. 2000;523:403–411.PubMedCentralCrossRefPubMed Page AJ, O’Donnell TA, Blackshaw LA. P2X purinoceptor-induced sensitization of ferret vagal mechanoreceptors in oesophageal inflammation. J Physiol. 2000;523:403–411.PubMedCentralCrossRefPubMed
31.
go back to reference McIlwrath SL, Davis BM, Bielefeldt K. Deletion of P2X3 receptors blunts gastro-oesophageal sensation in mice. Neurogastroenterol Motil. 2009;21:e66–e890.CrossRef McIlwrath SL, Davis BM, Bielefeldt K. Deletion of P2X3 receptors blunts gastro-oesophageal sensation in mice. Neurogastroenterol Motil. 2009;21:e66–e890.CrossRef
32.
go back to reference Banerjee B, Medda BK, Schmidt J, et al. Altered expression of P2X3 in vagal and spinal afferents following esophagitis in rats. Histochem Cell Biol. 2009;132:585–597.CrossRefPubMed Banerjee B, Medda BK, Schmidt J, et al. Altered expression of P2X3 in vagal and spinal afferents following esophagitis in rats. Histochem Cell Biol. 2009;132:585–597.CrossRefPubMed
33.
go back to reference Suzuki M, Mizuno A, Kodaira K, et al. Impaired pressure sensation in mice lacking TRPV4. J Biol Chem. 2003;278:22664–22668.CrossRefPubMed Suzuki M, Mizuno A, Kodaira K, et al. Impaired pressure sensation in mice lacking TRPV4. J Biol Chem. 2003;278:22664–22668.CrossRefPubMed
34.
go back to reference Shikano M, Ueda T, Kamiya T, et al. Acid inhibits TRPV4-mediated Ca2+ influx in mouse esophageal epithelial cells. Neurogastroenterol Motil. 2011;23:1020–1028.CrossRefPubMed Shikano M, Ueda T, Kamiya T, et al. Acid inhibits TRPV4-mediated Ca2+ influx in mouse esophageal epithelial cells. Neurogastroenterol Motil. 2011;23:1020–1028.CrossRefPubMed
35.
go back to reference Awayda MS, Bengrine A, Tobey NA, et al. Nonselective cation transport in native esophageal epithelia. Am J Physiol Cell Physiol. 2004;287:C395–C402.CrossRefPubMed Awayda MS, Bengrine A, Tobey NA, et al. Nonselective cation transport in native esophageal epithelia. Am J Physiol Cell Physiol. 2004;287:C395–C402.CrossRefPubMed
36.
go back to reference Yamasaki T, Oshima T, Tomita T, et al. Effect of age and correlation between esophageal visceral chemosensitivity and mechanosensitivity in healthy Japanese subjects. J Gastroenterol. 2013;48:360–365.CrossRefPubMed Yamasaki T, Oshima T, Tomita T, et al. Effect of age and correlation between esophageal visceral chemosensitivity and mechanosensitivity in healthy Japanese subjects. J Gastroenterol. 2013;48:360–365.CrossRefPubMed
37.
go back to reference Thorneloe KS, Cheung M, Bao W, et al. An orally active TRPV4 channel blocker prevents and resolves pulmonary edema induced by heart failure. Sci Transl Med. 2012;4:159ra148.CrossRefPubMed Thorneloe KS, Cheung M, Bao W, et al. An orally active TRPV4 channel blocker prevents and resolves pulmonary edema induced by heart failure. Sci Transl Med. 2012;4:159ra148.CrossRefPubMed
38.
go back to reference Lohman RJ, Cotterell AJ, Suen J, et al. Antagonism of protease-activated receptor 2 protects against experimental colitis. J Pharmacol Exp Ther. 2012;340:256–265.CrossRefPubMed Lohman RJ, Cotterell AJ, Suen J, et al. Antagonism of protease-activated receptor 2 protects against experimental colitis. J Pharmacol Exp Ther. 2012;340:256–265.CrossRefPubMed
Metadata
Title
Protease-Activated Receptor-2 Up-Regulates Transient Receptor Potential Vanilloid 4 Function in Mouse Esophageal Keratinocyte
Authors
Nobuhiro Suzuki
Hiroshi Mihara
Hirofumi Nishizono
Makoto Tominaga
Toshiro Sugiyama
Publication date
01-12-2015
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 12/2015
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-015-3822-6

Other articles of this Issue 12/2015

Digestive Diseases and Sciences 12/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.